GlassScriptPhysician profile
Edris Holland
NPI 1154929495
$5,022.01
in general payments reported to CMS, 2019-2025
26 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.71 · 2022: $175 · 2023: $1,083 · 2024: $1,805 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,715 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,715.11 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,216.31 | 2021-2025 | |
| Novo Nordisk INC | $831.69 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $733.94 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $566.53 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $297.90 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $250.49 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $173.35 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $119.07 | 2023-2024 | Linzess |
| Vertex Pharmaceuticals Incorporated | $116.23 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.02 | 2022-2025 | Jardiance, Synjardy |
| Mannkind Corporation | $93.71 | 2025 | |
| Tempus Ai, INC | $84.74 | 2024 | |
| Amgen INC. | $78.12 | 2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $53.01 | 2025 | Auvelity |
| Dexcom, INC. | $49.48 | 2024-2025 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.68 | 2024 | Xarelto |
| Shield Therapeutics INC | $38.13 | 2025 | |
| Verona Pharma, INC. | $29.53 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $28.95 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $19.70 | 2025 | Cobenfy |
| Phadia US INC. | $19.17 | 2024 | Immunocap |
| Biohaven Pharmaceutical Holding Company LTD. | $18.38 | 2022 | |
| Vision Quest Industries INC. | $17.46 | 2024 | Oactive Align Custom R |
| Radius Health, INC. | $17.23 | 2023 | |
| Nestle Healthcare Nutrition INC. | $13.76 | 2022 | |
| Smith+Nephew, INC. | $13.43 | 2023 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edris Holland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.